Probody therapeutics for targeting antibodies to diseased tissue

作者：Krishna R. Polu, Henry B. Lowman · 发表于：Expert Opinion on Biological Therapy · 年份：2014 · DOI：10.1517/14712598.2014.920814 · 被引用次数：85 · 研究领域：Monoclonal and Polyclonal Antibodies Research、CAR-T cell therapy research、Glycosylation and Glycoproteins Research

Probodies are proteolytically activated antibodies engineered to remain inert until activated locally in diseased tissue. In principle, any therapeutic antibody can be converted into Probody™ form. In this perspective, we highlight the emerging therapeutic potential of the Probody approach in the form of conventional IgG-based Probodies as well as in the form of 'empowered Probody' formats such as Probody-drug conjugates.